Summary
Annexon: Preserving Patient Function Is The Real Investment Opportunity
Annexon targets functional patient outcomes in geographic atrophy and Guillain-Barré syndrome, aiming for clinical differentiation via vision and physical recovery preservation. ANNX maintains a cash runway into 2028, supported by $209.2M in liquidity and a $200M Oxford Finance facility, but future financing remains a risk. The ARCHER II trial pivots to functional vision endpoints, with key readouts expected in Q4 2026 and potential market expansion if vision preservation is confirmed.
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
Annexon Q2 Earnings Call Highlights
Annexon NASDAQ: ANNX said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study's existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the 15-month endpoint while seeking to capture longer-term efficacy data for a potential product label.
Annexon, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 249 | $1,354.57 | $896.4 | -$458.17 | -33.82% |
| NA Nizar Araji National Bank Of Canada /FI/ | 67 | $382.57 | $241.2 | -$141.37 | -36.95% |
| BG Bart Gancher Intech Investment Management LLC | 29,929 | $106,733.29 | $107,744.4 | $1,011.11 | 0.95% |
| JFB John F. Brennan, Jr. Sirios Capital Management LP | 569,276 | $1.2M | $2.05M | $846,872.11 | 70.42% |
| KJD Kathryn J. Daniels Canada Pension Plan Investment Board | 40,800 | $216,880 | $139,128 | -$77,752 | -35.85% |
Annexon, Inc. (ANNX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Annexon, Inc. ever had a stock split?
Annexon, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Douglas E. Love CEO | NASDAQ (NGS) Exchange | 03589W102 CUSIP |
| US Country | 92 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Annexon, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of medicines designed to address inflammatory diseases. The company has made significant strides in developing treatments that target the underlying mechanisms of these conditions. Incorporated in 2011, Annexon is headquartered in Brisbane, California, and has dedicated itself to advancing a broad pipeline of therapeutic candidates that have the potential to provide new treatment options for patients with serious and often underserved medical needs.
Products and Services
Annexon, Inc. has a diverse portfolio of product candidates in various stages of clinical development. These include:
- ANX005: This lead candidate is a full-length monoclonal antibody currently in a Phase 3 clinical trial for the treatment of Guillain-Barré syndrome, a rare neurological disorder. ANX005 has also completed a Phase II clinical trial for Huntington's disease and is in a Phase II clinical trial for amyotrophic lateral sclerosis (ALS), targeting different aspects of inflammatory-related diseases.
- ANX007: An antigen-binding fragment (Fab) designed to treat patients with geographic atrophy, an advanced form of age-related macular degeneration. ANX007 is in a Phase 3 program, representing Annexon’s commitment to addressing severe ocular diseases through cutting-edge therapies.
- ANX1502: This novel oral small molecule inhibitor is being tested in Phase 1 clinical trials for autoimmune indications. ANX1502 signifies Annexon's exploration into oral therapeutics for autoimmune diseases, expanding the company's portfolio beyond monoclonal antibodies and Fabs.
- ANX009: A C1q-blocking Fab in Phase I clinical trial aimed at treating patients with lupus nephritis. This candidate highlights Annexon's approach to targeting specific elements of the immune system to combat autoimmune diseases.
Contact Information
